Clinical Trials in Arizona

Showing 1381-1400 of 14,395 trials

Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis

NCT06668493

The primary purpose of this trial is to evaluate the safety \& tolerability of Nadofaragene Firadenovec in subjects with LG-UTUC. To help with this evaluation, a safety lead-in period will be conducted for the first 6 subjects. Complete response is at 3 or 6 months defined as absence of any UTUC in the renal pelvis.

Low-grade Upper Tract Urothelial Carcinoma

Ferring Pharmaceuticals20 participantsStarted Jun 2025

Scottsdale, Arizona, United States • Jacksonville, Florida, United States • Indianapolis, Indiana, United States +4 more locations

RECRUITINGPhase 331 miles

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

NCT07184996

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis (UC). Study details include: The study duration may be up to 35 weeks with: * Screening period * 12-week Sub-Study 1 (Single-Arm Open-Label Feeder Induction) or Sub-Study 2 (Pivotal Induction) * 12-week Sub-Study 3 (Extended Induction for non-responders) * 45 days follow-up visit for participants who do not enroll into the maintenance study (EFC18359) The treatment duration will be up to 12 weeks in each sub-study. The number of scheduled on-site visits will be up to 8 for the Sub-Study 1 and Sub Study 2 or a maximum of 15 visits for participants completing extended induction.

Ulcerative Colitis

Sanofi980 participantsStarted Oct 2025

Peoria, Arizona, United States • Scottsdale, Arizona, United States • Tucson, Arizona, United States +85 more locations

Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Find Trials by Condition in Arizona

WatchWell: Simple and Practical Strategies to Reduce the Negative Health Impact of Sedentary Screen Time

Clinical Validation of the RENISCHEM L-FABP POC Assay

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

The ENCIRCLE Trial

Prophylactic Reinforcement of Ventral Abdominal Incisions Trial

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range

GCC19CART for Patients With Metastatic Colorectal Cancer

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

Oral N-acetylcysteine for Retinitis Pigmentosa

Primary Tumor Research and Outcomes Network

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Motor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds)

The RESET Clinical Trial: SPRINT® Peripheral Nerve Stimulation for the Treatment of Back Pain

Reducing Potentially Inappropriate Medication Prescribing for Older Patients in the ED

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

Effect of Donor Diabetes and Other Factors on Corneal Transplant Endothelial Cell Loss and Success at 5 Years